老年人群皮内与肌内接种灭活流感疫苗的免疫应答
一项前瞻性、开放标签、随机研究纳入221名60岁以上成人,比较皮内与肌内接种灭活季节性流感疫苗的免疫应答;皮内组对H1N1和H3N2的血清转化率高于肌内组,但对B/Phuket无差异;总体血清转化率中等,尤其在65岁以上人群。
要点
- 皮内组对H1N1和H3N2的血清转化率高于肌内组,对B/Phuket无差异。
- 皮内组对A/California/07/09(H1N1)和A/Songkha/308/13(H3N2)的血清转化率风险比分别为1.31和1.25。
- 总体血清转化率中等,尤其在65岁以上人群。
核心结论
- 皮内与肌内接种灭活流感疫苗的血清转化率中等,尤其在65岁以上人群,但皮内组高于肌内组。
研究设计与样本
- 前瞻性、开放标签、随机研究,共纳入221名60岁以上成人,随机分为两组:肌内组111人,皮内组110人。
- 基线收集人口学与共病信息,接种后3天通过日记卡收集安全性数据,接种前及接种后30、45、60天评估HAI、NAb和NAI滴度。
主要发现
- 皮内组与肌内组对H1N1的HAI血清转化率分别为58/111与44/110,对H3N2分别为68/111与54/110,均在60-65岁人群中更高。
- 两组对B/Phuket的HI抗体无差异。
- 皮内组对A/California/07/09(H1N1)和A/Songkha/308/13(H3N2)的血清转化率风险比分别为1.31和1.25(p < .05)。
- 两组基线NAI抗体GMT(95% CI)较高,皮内组为56.57,肌内组为54.01。
- NAI对A/California/07/09(H1N1)4倍升高的比例在皮内组为16.67%,肌内组为20%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUD: Influenza viruses cause substantial morbidity, especially in older age groups. Thus, they are amongst high priority groups for routine vaccination. However, vaccine-induced immune responses and effectiveness were reported as relatively low. This study aims to systemically compare the immune responses elicited by intramuscular (IM) and intradermal (ID) injections with inactivated seasonal influenza vaccine among the older age group. METHODS: A prospective, open-label, randomized study with a total of 221 adults (>60 years) were enrolled and randomized into 2 groups. Group I (n = 111) received an IM inactivated seasonal influenza vaccine while Group II (n = 110) received the same vaccine ID. Demographics and co-morbidity were collected at baseline. Safety data was collected 3 days post-vaccination using diary card. HAI, NAb and NAI titers were assessed prior to vaccination and at 30, 45, and 60 days post-vaccination. Data was analyzed using SPSS 11.5. RESULTS: Both groups had similar BMI and co-morbidity. For ID and IM groups, significant differences were observed for seroconversion rate measured using HAI against H1N1 and H3N2 (58/111 vs 44/110 and 68/111 vs 54/110, respectively) being higher for those aged 60-65 years. However, no differences in HI antibody against B/Phuket were seen. For ID route, history of hyperlipidemia and hypertension were factors associated with high seroconversion rate towards influenza A (p = .001). The seroconversion rate risk ratio were 1.31 and 1.25 (p < .05) against A/California/07/09(H1N1) and A/Songkha/308/13 (H3N2), respectively. Interestingly, the GMT (95% CI) of baseline NAI antibodies among both groups were high (56.57 and 54.01 in the ID and IM groups, respectively). A 4-fold increase measured by NAI against A/California/07/09 (H1N1) were detected in 16.67% and 20% of participants who received ID or IM vaccination, respectively. CONCLUSIONS: The seroconversion rates of HAI, NAb and NAI were modest, especially in those >65 years of age. However, it was higher in the ID group as compared to the IM group. CLINICAL TRIAL REGISTRATION: NCT02101749.
引用
- Boonnak K, Dhitavat J, Thantamnu N, et al. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group. Vaccine. 2017. PMID: 29157960. doi:10.1016/j.vaccine.2017.10.106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。